Navigation Links
OncoSec Medical to Present at the 15th Annual BIO CEO & Investor Conference
Date:2/6/2013

able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives.  OncoSec Medical's core technology is based upon its proprietary use of an electroporation platform to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at http://www.oncosec.com/.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward look
'/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OncoSec Medical to Present at Noble Financial Capital Markets Ninth Annual Equity Conference on January 22
2. OncoSec Medical Announces $7.2 Million Public Offering
3. OncoSec Medical to Present Data at DNA Vaccines 2012 Conference
4. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
5. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
6. OncoSec to Present at Upcoming Healthcare and Investor Conferences
7. OncoSec Granted New Patent from China
8. OncoSec to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
9. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
10. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
11. OncoSec Establishes Clinical Site for Its Phase II Merkel Cell Carcinoma Trial at University of California San Francisco (UCSF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 As health officials across the ... select Meijer pharmacies in Michigan will ... eligible patients, enabling Meijer pharmacists to administer tests and, in ... by a physician participating in the study. The ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... commitments from institutional investors to purchase an aggregate of ... an at-the-market registered direct offering, led by a dedicated ... definitive purchase agreements with these investors pursuant to which ...
(Date:1/15/2014)... FORT WORTH, Texas , Jan. 15, 2014  Humberto ... in Dermatology Achievement Award" from the Journal of ... Dermatology Aesthetic & Clinical Conference (ODAC). The event is January ... Florida . The ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... 2010 Renal Advantage and Liberty Dialysis, which last month ... dialysis services in the U.S., today announced that they have ... not disclosed – was completed on December 17, 2010.  The ... in 260 locations in 32 states. "The completion ...
... 22, 2010 Particle Sciences Inc. (PSI), a leading ... that, when coupled with an antigen, enhanced its immunogenicity, ... work is described in Vaccine , 2010 Dec. ... strong systemic and mucosal cellular and humoral immune responses ...
Cached Medicine Technology:Renal Advantage and Liberty Dialysis Deal Completed 2Renal Advantage and Liberty Dialysis Deal Completed 3Particle Sciences Develops Wax Nanoparticles that Enhance Immune Response to Antigens 2
(Date:4/17/2014)... Boston University School of Medicine (BUSM) have discovered ... in an experimental model. The findings, reported in ... Abuse , may lead to more effective treatments ... one of the leading causes of illness and ... economic impact by limiting the productivity of workers ...
(Date:4/17/2014)... team led by researchers at UC Davis has shown ... key role in cell division, also boosts the mitochondrial ... time the complex has been shown to perform both ... excellent target to control cellular energy production, potentially advancing ... online today in the journal Developmental Cell . ...
(Date:4/17/2014)... led by Cesar A. Arias, M.D., Ph.D., at The ... has identified a new superbug that caused a bloodstream ... the April 17 issue of The New England ... part of a class of highly-resistant bacteria known as ... a major cause of hospital and community-associated infections. The ...
(Date:4/17/2014)... uncommon these days to find a colored ribbon representing a ... cancer. But what color ribbon does one think of with ... color, for many suffering from the disease, black may be ... study consisting of lung cancer patients, primarily smokers between the ... light on the stigma often felt by these patients, the ...
(Date:4/17/2014)... alleviates muscle soreness after exercise, according to a ... at Chicago. , The study, reported online in ... Physical Medicine and Rehabilitation , also showed that ... not exercised, suggesting that massage has benefits for ... , Improved circulation and relief of muscle soreness ...
Breaking Medicine News(10 mins):Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:New MRSA superbug emerges in Brazil 2Health News:Unraveling the 'black ribbon' around lung cancer 2Health News:Massage therapy improves circulation, eases muscle soreness 2
... investments in nanoscale science and engineering will create revolutions ... treatment, and space travel. The hope is that many ... nanotechnology enabled products. While new technologies often do ... other social problems or create entirely new ones. The ...
... Reporter , THURSDAY, Nov. 18 (HealthDay News) -- Patients in ... because of cost than residents of other developed countries, a ... industrialized countries, the United States also has the highest out-of-pocket ... "The 2010 survey findings point to glaring gaps in ...
... into mice with metastatic melanoma has resulted in permanent ... cancer, according to an article to be published in ... Clinical Investigation . The online version is now available. ... modified lentivirus to introduce a potent anti-melanoma T cell ...
... nice extra, not a strategic imperative. But the data demonstrate ... L. Berry of Texas A&M University, Ann M. Mirabito of ... Texas MD Anderson Cancer Center. Their research shows that ... is impressive sometimes as high as six to one. ...
... WASHINGTON, Nov. 18, 2010 The latest episode in ... Global Challenges/Chemistry Solutions ," focuses on development and successful ... kills up to 98 percent of disease-causing bacteria in ... technology could aid many of the almost one billion ...
... Ill. -- Taking time off from certain osteoporosis drugs may ... at Loyola University Health System. Researchers found that bone density ... drug holiday from bisphosphonates, a popular class of osteoporosis drugs ... decay in the jaw bone. "These drugs are potentially ...
Cached Medicine News:Health News:Nanotechnology and equity issues explored in new book 2Health News:On Health Policies, U.S. Lags Other Nations: Survey 2Health News:On Health Policies, U.S. Lags Other Nations: Survey 3Health News:On Health Policies, U.S. Lags Other Nations: Survey 4Health News:Gene therapy for metastatic melanoma in mice produces complete remission 2Health News:Wellness programs provide high returns, research reveals 2Health News:Taking a break from osteoporosis drugs can protect bones 2
... The PK Super-Sect is a ... tissue removal with minimal thermal spread ... for superior hemostatis. It can be ... gland and/or bladder tumor. It is ...
... CS is a fully ... treatment system designed to ... unlimited flexibility. Cryocare CS ... specific physician needs through ...
... Oncura's SeedNet system is a minimally invasive ... to learn and simple to use, SeedNet ... the cryoablation process. SeedNet is the ... Ultra-thin needles, exclusive to the SeedNet system, ...
Medium Clip Appliers. American-made stainless steel, 6" long, curved tip. For use with VE-6-25 and VE-6-10 titanium surgical clips only....
Medicine Products: